{"schema_version":"secwatch.filing_event.v1","accession":"0001503274-25-000004","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.816849+00:00","generated_at":"2026-05-28T04:52:52.392102+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Quanterix to acquire Akoya Biosciences; expands addressable market to $5B","bullets":["Transaction expected to close in Q2 2025; combined cash at close ~$175M.","Combined installed base of 2,300+ instruments; addressable market grows from $1B to $5B.","Expands Quanterix from neurology into oncology and immunology via Akoya's tissue biomarker platform.","Post-closing, combined company will operate under Quanterix name; integration team being formed."],"urls":{"canonical":"https://secwatch.observer/filing/0001503274-25-000004","json":"https://secwatch.observer/filing/0001503274-25-000004.json","markdown":"https://secwatch.observer/filing/0001503274-25-000004.md","text":"https://secwatch.observer/filing/0001503274-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000004/0001503274-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000004/qtrx-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:52:52.392102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}